Gary Middleton, Helen Robbins, Fabrice André, Charlie Swanton (2021, Nov 19; DOI: /10.1016/j.annonc.2021.11.004). A state-of the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer. Annals of Oncology
Lennard Y.W. Lee, Thomas Hill, Oliver Topping, Michael Tilby, Mark Baker, Julian Greig … Gary Middleton, on behalf of the UK Birmingham Chemotherapy Cancer COVID-19 Project (2020, Sept 14; DOI: 10.1016/j.ccell.2020.07.009). Utility of COVID-19 screening in cancer patients. Cancer Cell
Lennard Y W Lee, Jean-Baptiste Cazier, Thomas Starkey, Sarah E W Briggs, Roland Arnold … Gary Middleton, Rachel Kerr, on behalf of the UK Coronavirus Cancer Monitoring Project Team (2020 Oct 1; DOI: 10.1016/S1470-2045(20)30442-3). COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics. Lancet Oncology
Gary Middleton, Kristian Brock, Joshua Savage, Rhys Mant, Yvonne Summers, John Connibear … Lucinda Billingham (2020, Sept; DOI: 10.1016/S2213-2600(20)30033-3). Pembrolizumab in patients with non-small cell lung cancer and a performance status of 2 (PePS2): a single-arm phase II trial. Lancet Respiratory Medicine.
Oliver J Pickles, Aneta Drozd, Louise Tee, Andrew D Beggs, Gary W Middleton (2020, Aug; DOI: 10.18632/oncotarget.27681) Paradox breaker BRAF inhibitors have comparable potency and MAPK pathway reactivation to encorafenib in BRAF mutant colorectal cancer. Oncotarget
Gary Middleton, Peter Fletcher, Sanjay Popat , Joshua Savage , Yvonne Summers … Charles Swanton, Lucinda Billingham (2020, July 15; DOI: 10.1038/s41586-020-2481-8). The National Lung Matrix Trial of personalized therapies in lung cancer. Nature.
Lennard YW Lee, Jean-Baptiste Cazier, Vasileios Angelis, Roland Arnold, Vartika Bisht, Naomi A Campton … Gary Middleton, on behalf of the UK Coronavirus Cancer Monitoring Project Team (2020, June 16; DOI: 10.1016/S0140-6736(20)31173-9). COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments. The Lancet
Oliver J. Pickles, Lennard Y. W. Lee, Thomas Starkey, Luke Freeman-Mills, Anna Olsson-Brown, Vinton Cheng … Gary Middleton (2020, June 16; DOI: 10.1038/s41416-020-0930-7). Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome? British Journal of Cancer
Valerie Pestinger, Matthew Smith, Toju Sillo, John M. Findlay, Jean-Francois Laes, Gerald Martin, Gary Middleton, Phillipe Taniere, Andrew D. Beggs (2020, June 1; DOI: 10.1007/s40291-020-00462-x) Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants. Molecular Diagnosis and Therapy
Gary Middleton, Yiqun Yang, Catarina D. Campbell, Thierry André, Chloe E. Atreya, Jan H.M. Schellens … Ryan B. Corcoran (2020, Feb 11; DOI: 10.1158/1078-0432.CCR-19-3579). BRAF-mutant transcriptional subtypes predict outcome of combined BRAF, MEK, and EGFR blockade with dabrafenib, trametinib, and panitumumab in patients with colorectal cancer. Clinical Cancer Research
Akshay J. Patel, Alex Richter, Mark T. Drayson, Gary W. Middleton (2020, Jan 4; DOI: 10.1007/s00262-019-02461-2). The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer. Cancer Immunology, Immunotherapy
Livingstone F., Panetti S., Margaret N., Collins P., Graef S., Nagy S., Booth S., Lenton R., Noyvert B, Shannon-Lowe C., Middleton G., Mussai F., De Santo C. (2019, Sept; DOI: 10.1016/j.ebiom.2019.08.025) MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. Ebiomedicine
Swati Khanna, Suzanne Graef, Francis Mussai, … Gary Middleton (senior author), Carmela De Santo, Raffit Hasan (2018, March 30: DOI: 10.1158/1078-0432.CCR-17-3757) Tumour-derived GM-CSF promotes granulocyte immunosuppression in mesothelioma patients. Clinical Cancer Research
Neeraj Lal, Brian S White, Ghaleb Goussous, Oliver Pickles, Mike J Mason, Andrew D Beggs … Gary W Middleton (2017, Oct 23; DOI: 10.1158/1078-0432.CCR-17-1090). KRAS mutation and Consensus Molecular Subtypes 2 and 3 are independently associated with reduced immune infiltration and reactivity in colorectal cancer Clinical Cancer Research
Neeraj Lal, Andrew Beggs, Benjamin Willcox, Gary Middleton (2015 Apr 2; DOI: 10.4161/2162402X.2014.976052) An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. Oncoimmunology.
View all publications in research portal